Medical Advisory Board Chairman Dr. Sam Alawieh explains, "The general industry consensus continues to drive market focus on seed to sale and access to product as the critical elements for medical marijuana as an industry to succeed; we believe that science is the foundation required for success. It is our belief that strong science will layout the critical components of patients taking their medicine in the future. For example, having a real drug side effect profile or taking a strain with specific dosing customized for the patient based on a DNA saliva swab. Scientific studies are so desperately needed with cannabis and its active products".
Bill Chaaban, President & CEO adds, "We are assembling an unparalleled group of world renown physicians and researchers. Our company vision believes in innovation and research as the key to success and future profitability. Research and development will lead to the ownership of intellectual property. It is our belief that the true value in this industry lies in the ownership of intellectual property. To achieve this goal, we have put together divisions that we believe will allow us to execute our vertical integration vision from science to seed to sale."
Dr. Sam Alawieh continued to state, "The Research & Development Divisions Include: Genetic Engineering & Cloning, Genomic DNA Mapping & Strain Analytics, Extracts & Delivery Instruments, Pharmacogenetic & Clinical Trials, and Stem Cell & Tissue Proliferation.
"We are proud to announce a prominent research division, Stem Cell & Tissue Proliferation, adding Dr. Jonathan Lakey as the Chief Science Officer; an incredible expert in the field of medical research who will be researching initiatives in marijuana & hemp plant stem cells, plant cell cycles, tissue development acceleration, and the effects of Medical Marijuana on stem cell development including proliferation, differentiation down key developmental pathways," explained Dr. Sam Alawieh.
"I'm excited to be on this project and team; allowing for science to really dictate a responsible path of medicine which patients so desperately need." Dr. Lakey passionately described, "It is my goal to take the expertise and infrastructure I have developed over the years and apply it to the field of this research, strong evidence based science will address common misconceptions and provide scientific basis for our efforts. By studying effects of stem cells and differentiation we may gain key insight into pathways of disease treatments and wound healing. Bill Chaaban has done a great job emphasizing that this is the route necessary to take and I couldn't agree more."
Bill Chaaban stated, "From Day 1, we made the decision to overlook the principle of first to market because we believed in building from the ground up a model that is first to quality. The research division will allow us the ability to lay the necessary foundational upgrades driving the vision of eventually providing the best products to our patients."
Dr. Jonathan Lakey has a long history of innovative and ground breaking research leading to clinical changes in patient care and treatments. Dr. Lakey is an Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine, California. He is a faculty member at the Sue and Bill Gross Stem Cell Center, a CIRM funded institute focused on stem cell research focused on translating technologies into clinical practice.
Dr. Lakey's innovative and groundbreaking research earned him a compelling list of academic accolades over his scientific career including the Meritorious Service Medal from the Governor General of Canada. Dr. Lakey has been published in numerous research articles for his incredible work in the field of diabetes research, stem cells and tissue transplantation with over 250 scientific publications, 30 book chapters and notable patents in wide ranging fields of biomedical research. Dr. Lakey is a widely sought after public and scientific speaker and has had several collaborations with biotechnology companies translating scientific discovery into clinical practice.
In the past week, site 1 has been groomed and is operationally prepared to grow medical cannabis. It is important to note that ground maintenance and cleanliness is an important component of GMP. Our team has conducted multiple dry runs and believes that we are operationally prepared to operate a GMP medical cannabis facility.
can u see it yet?
